Xiaobin Wu insider trades: BeOne Medicines (ONC) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Xiaobin reports to the SEC
Open-market buys and sales
39 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | ONC | ↓ Sell | 280 | $380.00 | $106K | Direct | Aug 27, 2026 (2d) |
| Jun 16, 2026 | ONC | ↓ Sell | 1,357 | $266.76 | $362K | Direct | Jun 18, 2026 (2d) |
| Jun 11, 2026 | ONC | ↓ Sell | 626 | $261.20 | $164K | Direct | Jun 15, 2026 (4d) |
| Jun 8, 2026 | ONC | ↓ Sell | 1,484 | $269.37 | $400K | Direct | Jun 10, 2026 (2d) |
| Nov 17, 2025 | ONC | ↓ Sell | 3,991 | $380.43 | $1.5M | Direct | Nov 19, 2025 (2d) |
| Nov 13, 2025 | ONC | ↓ Sell | 16,009 | $365.22 | $5.8M | Direct | Nov 14, 2025 (1d) |
| Aug 14, 2025 | ONC | ↓ Sell | 89,794 | $304.56 | $27.3M | Direct | Aug 15, 2025 (1d) |
| Jun 23, 2025 | ONC | ↓ Sell | 1,363 | $260.00 | $354K | Direct | Jun 25, 2025 (2d) |
| Jun 17, 2025 | ONC | ↓ Sell | 2,173 | $261.27 | $568K | Direct | Jun 18, 2025 (1d) |
| Jun 6, 2025 | ONC | ↓ Sell | 1,934 | $253.15 | $490K | Direct | Jun 10, 2025 (4d) |
| Apr 1, 2025 | BGNE | ↓ Sell | 51,921 | $281.40 | $14.6M | Direct | Apr 3, 2025 (2d) |
| Mar 5, 2025 | BGNE | ↓ Sell | 51,921 | $261.59 | $13.6M | Direct | Mar 7, 2025 (2d) |
| Feb 20, 2025 | BGNE | ↓ Sell | 51,921 | $240.46 | $12.5M | Direct | Feb 20, 2025 (0d) |
| Sep 19, 2024 | BGNE | ↓ Sell | 5,000 | $200.12 | $1.0M | Direct | Sep 19, 2024 (0d) |
| Sep 3, 2024 | BGNE | ↓ Sell | 5,556 | $189.65 | $1.1M | Direct | Sep 5, 2024 (2d) |
| Jun 24, 2024 | BGNE | ↓ Sell | 1,459 | $159.79 | $233K | Direct | Jun 26, 2024 (2d) |
| Jun 18, 2024 | BGNE | ↓ Sell | 3,254 | $155.26 | $505K | Direct | Jun 20, 2024 (2d) |
| Jun 26, 2023 | BGNE | ↓ Sell | 1,495 | $182.36 | $273K | Direct | Jun 27, 2023 (1d) |
| Jun 20, 2023 | BGNE | ↓ Sell | 1,753 | $192.44 | $337K | Direct | Jun 20, 2023 (0d) |
| Jun 7, 2023 | BGNE | ↓ Sell | 3,291 | $224.73 | $740K | Direct | Jun 9, 2023 (2d) |
| May 8, 2023 | BGNE | ↓ Sell | 7,000 | $253.72 | $1.8M | Direct | May 10, 2023 (2d) |
| Jun 21, 2022 | BGNE | ↓ Sell | 1,588 | $142.63 | $226K | Direct | Jun 22, 2022 (1d) |
| Jun 6, 2022 | BGNE | ↓ Sell | 3,410 | $141.99 | $484K | Direct | Jun 8, 2022 (2d) |
| May 5, 2022 | BGNE | ↓ Sell | 6,725 | $164.35 | $1.1M | Direct | May 6, 2022 (1d) |
| Nov 9, 2021 | BGNE | ↓ Sell | 10,000 | $358.27 | $3.6M | Direct | Nov 10, 2021 (1d) |
| Jul 6, 2021 | BGNE | ↓ Sell | 10,180 | $325.53 | $3.3M | Direct | Jul 8, 2021 (2d) |
| Jun 18, 2021 | BGNE | ↓ Sell | 1,156 | $330.93 | $383K | Direct | Jun 21, 2021 (3d) |
| Jun 7, 2021 | BGNE | ↓ Sell | 3,398 | $352.54 | $1.2M | Direct | Jun 9, 2021 (2d) |
| May 3, 2021 | BGNE | ↓ Sell | 6,715 | $343.00 | $2.3M | Direct | May 5, 2021 (2d) |
| Oct 5, 2020 | BGNE | ↓ Sell | 4,000 | $300.00 | $1.2M | Direct | Oct 7, 2020 (2d) |
| Sep 25, 2020 | BGNE | ↓ Sell | 4,000 | $280.35 | $1.1M | Direct | Sep 29, 2020 (4d) |
| Sep 17, 2020 | BGNE | ↓ Sell | 4,000 | $260.33 | $1.0M | Direct | Sep 21, 2020 (4d) |
| Jul 20, 2020 | BGNE | ↓ Sell | 3,300 | $249.22 | $822K | Direct | Jul 21, 2020 (1d) |
| Jul 15, 2020 | BGNE | ↓ Sell | 5,700 | $230.00 | $1.3M | Direct | Jul 15, 2020 (0d) |
| Jun 8, 2020 | BGNE | ↓ Sell | 2,800 | $170.83 | $478K | Direct | Jun 10, 2020 (2d) |
| May 1, 2020 | BGNE | ↓ Sell | 7,024 | $141.33 | $993K | Direct | May 5, 2020 (4d) |
| Nov 15, 2019 | BGNE | ↓ Sell | 1,000 | $202.05 | $202K | Direct | Nov 18, 2019 (3d) |
| Nov 1, 2019 | BGNE | ↓ Sell | 1,000 | $180.00 | $180K | Direct | Nov 5, 2019 (4d) |
| May 1, 2019 | BGNE | ↓ Sell | 5,955 | $124.52 | $742K | Direct | May 2, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ONC insiders
Open-market trades in the last 12 months
About Xiaobin Wu's insider trades
Xiaobin Wu is President and COO at BeOne Medicines (ONC). Since May 1, 2019, Xiaobin has reported no open-market purchases and 39 sales worth $104.4M on SEC Form 4. In the last 12 months: 6 sales ($8.4M).
Their filings also include grants and awards (12 filings), option exercises (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ONC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.